1 Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263. 2 Rettig EM,D′Souza G.Epidemiology of head and neck cancer:Emerging trends[J].Oral Oncol,2023,138:106328. 3 Zheng R,Zhang S,Zeng H,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2023,3(1):1-12. 4 Chow LQM.Head and Neck Cancer[J].New England Journal of Medicine,2020,382(1):60-72. 5 Constantin M,Chiffriuc MC,Bleotu C,et al.Molecular pathways and targeted therapies in head and neck cancers pathogenesis[J].Frontiers in Oncology,2024,14:1373821. 6 周琴,张琨,伍海军,等.头颈部鳞状细胞癌的免疫治疗进展[J].中国医师杂志,2021,23(11):1605-1610,1615. 7 Owens D,Paleri V,Jones AV.Head and neck cancer explained:an overview of management pathways[J].British Dental Journal,2022,233:721-725. 8 郭建贵,胡学锋,刘桂超,等.局部晚期头颈部鳞癌术后放疗联合尼妥珠单抗或奈达铂治疗疗效的比较[J].现代医药卫生,2021,37(20):3512-3516. 9 Ikeda M,Matsuzuka T,Kakamu T,et al.Feasibility of totally implantable venous access ports in the upper arm for patients with head and neck cancer in the modern era of chemotherapy[J].The Journal of Vascular Access,2024:11297298241279623. 10 Bizzoca ME,Caponio VCA,LO Muzio L,et al.Methods for overcoming chemoresistance in head and neck squamous cell carcinoma:keeping the focus on cancer stem cells,a Systematic Review[J].Cancers,2024,16(17):3224. 11 Cooper JS,Pajak TF,Forastiere AA,et al.Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck[J].New England Journal of Medicine,2004,350(19):1937-1944. 12 Gili R,Gianluca S,Paolo A,et al.The role of prehabilitation in HNSCC patients treated with chemoradiotherapy[J].Supportive Care in Cancer,2024,32(10):798. 13 Bernier J,Domenge C,Ozsahin M,et al.Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer[J].New England Journal of Medicine,2004,350(19):1945-1952. 14 Lacas B,Carmel A,Landais C,et al.Meta-analysis of chemotherapy in head and neck cancer(MACH-NC):An update on 107 randomized trials and 19,805 patients,on behalf of MACH-NC Group[J].Radiotherapy and Oncology,2021,156:281-293. 15 Wozniak G,Misiolek M,IDASIAK A,et al.Randomised clinical trial on 7-days-a-week postoperative radiotherapy vs. concurrent postoperative radio-chemotherapy in locally advanced cancer of the oral cavity/oropharynx[J].British Journal of Radiology,2020,93(1116):20200288. 16 Tasoulas J,Lenze NR,Farquhar D,et al.The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC[J].Cancer Medicine,2021,10(10):3231-3239. 17 Tsai YT,Chen WC,Wen YW,et al.Prognostic significance of adjuvant therapy and specific radiation dosages in Taiwanese patients with oral cavity cancer and extra-nodal extension:a nationwide cohort study[J].BMC Cancer,2024,24(1):1320. 18 Bernier J,Domenge C,Ozsahin M,et al.Defining risk levels in locally advanced head and neck cancers:a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC(#22931)and RTOG(#9501)[J].Head & Neck,2005,27(10):843-850. 19 Woody NM,Ward MC,Koyfman SA,et al.Adjuvant chemoradiation after surgical resection in elderly patients with high-risk squamous cell carcinoma of the head and neck:a national cancer database analysis[J].International Journal of Radiation Oncology,Biology,Physics,2017,98(4):784-792. 20 Verma M,Chakrabarti D.Are the classical indications of postoperative chemoradiotherapy in head and neck squamous cell cancers valid in the era of neoadjuvant chemotherapy?[J].Oral Oncology,2020,107:104731. 21 Gurizzan C,Cinquini M,Legramandil,et al.Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation:results of a meta-analysis of published trials[J].Therapeutic Advances in Medical Oncology,2024,17:17588359211022837. 22 Buglione M,Alterio D,Maddal M,et al.Three weekly versus weekly concurrent cisplatin:safety propensity score analysis on 166 head and neck cancer patients[J].Radiation Oncology,2021,16(1):1-9. 23 DE Felice F,Belgioia L,Alteiro D,et al.Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer:A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology(AIRO)[J].Critical Reviews in Oncology/Hematology,2021,162:103345. 24 Cardellini S,Trevisan F,Deantoni CL,et al.Nephrotoxicity in locally advanced head and neck cancer:when the end justifies the means to preserve nutritional status during chemoradiation[J].Supportive Care in Cancer,2024,33(1):13. 25 National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology for head and neck cancer(Version 1.2023)[EB/OL].[2023-01-01]. 26 Machiels JP,Leemans CR,Golusinski W,et al.Squamous cell carcinoma of the oral cavity,larynx,oropharynx and hypopharynx:EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis,treatment and follow-up[J].Annals of Oncology,2020,31(11):1462-1475. 27 National Comprehensive Cancer Network.NCCN Guidelines Version 2.2024 for Management of Chemotherapy Toxicities[EB/OL].2024. 28 Zhang Y,Chen L,Wang Z,et al.Liposomal cisplatin plus radiotherapy versus cisplatin plus radiotherapy in locally advanced head and neck squamous cell carcinoma:a multicenter phase III trial.Ann Oncol.2023;34(5):487-496. 29 Tao Y,Li X,Liu R,et al.Cetuximab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy in patients with locally advanced head and neck squamous cell carcinoma:a randomized,phase 3 trial.Lancet Oncol.2024,25(2):e76-e85. 30 Morse RT,Ganju RG,NeeranJun R,et al.Treatment tolerance of cetuximab versus alternative chemotherapy agents in non-cisplatin candidates with head and neck cancer receiving concurrent chemoradiotherapy[J].Chemotherapy,2023,68(1):35-43. 31 Han J,Zakeri K,Raab G,et al.Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer[J].Head & Neck,2023,45(9):2207-2216. 32 Ueki Y,Ohoshima S,Yokoyama Y,et al.Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma[J].International Journal of Clinical Oncology,2024,29(1):20-26. 33 Winkler LS,Haderlein M,Semrau S,et al.Treatment with(chemo)-radiation in old patients(≥76 years of age)with newly diagnosed non-metastatic squamous cell cancer of the head and neck region:real-world data from a tertiary referral center[J].Frontiers in Oncology,2024,14:1373821. 34 Kang EJ,Lee YG,Keam B,et al.Characteristics and treatment patterns in older patients with locally advanced head and neck cancer(KCSG HN13-01)[J].The Korean Journal of Internal Medicine,2022,37(1):190-200. 35 Chiliar F,Parisi S,Ferrantelli G,et al.Concurrent simultaneous integrated boost radiotherapy and cetuximab in head and neck squamous cell cancer patients:is it feasible in daily clinical practice?[J].Recenti Progressi in Medicina,2024,115(5):1e-6e. 36 Kut C,Quon H,Chen XS.Emerging radiotherapy technologies for head and neck squamous cell carcinoma:challenges and opportunities in the era of immunotherapy[J].Cancers,2024,16(24):4912. |